Subscribe to our Newsletters !!
An impact that could be devastating to human life
When conducting laboratory experiments, the choice
The human metapneumovirus, more simply referred to
Cipla Limited (BSE: 500087; NSE: CIPLA EQ) referre
Alembic Pharmaceuticals Limited (Alembic) announce
'Simplicity' seems to be the perfect word to descr
Welcome to the latest issue of Microbioz India. As
The final approval has been received from US health regulators to manufacture the Ibuprofen capsules, which is used as a pain reliever and fever reducer. Now the Aurobindo pharma will manufacture and do the marketing of Ibuprofen.
The launching of the product will be in September, 2018 and it’s the generic equivalent Pfizer's Advil Liqui-Gels Capsules.
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Ibuprofen capsules OTC, 200 mg," Aurobindo Pharma said in a BSE filing. .
"The company has received final approval from the US Food and Drug Administration (USFDA) to manufacture Ibuprofen capsules OTC, 200 mg," Aurobindo Pharma said in a BSE filing.
The estimated market size of ibuprofen capsules OTC is USD 164 million for the twelve months ending March 2018. The company has said that it has total of 373 ANDA (Abbreviated New Drug Application) approvals.
